(Q38119883)

29 August 2017

title

Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review (English)

1 reference

29 August 2017

1 reference

1 reference

1 reference

1 reference

Nkiruka Erekosima

1

1 reference

29 August 2017

Catalina Suarez-Cuervo

2

1 reference

29 August 2017

Murugappan Ramanathan

3

1 reference

29 August 2017

Julia M Kim

4

1 reference

29 August 2017

Yohalakshmi Chelladurai

5

1 reference

29 August 2017

Jodi B Segal

6

1 reference

29 August 2017

Sandra Y Lin

7

1 reference

29 August 2017

language of work or name

English

0 references

publication date

5 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

124

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

616-627

1 reference

The diagnosis and management of rhinitis: an updated practice parameter

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Allergen immunotherapy: a practice parameter third update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Comparison of two dosages of ragweed extract in the treatment of pollenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

House dust mite hyposensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Immunotherapy for mountain cedar pollinosis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

Immunotherapy: clinical trials--optimal trial and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

An update on the safety of specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.24295

21 January 2018

Identifiers

DOI

10.1002/LARY.24295

1 reference

29 August 2017

1 reference